Comment on OMB-2026-0034-0001

Summary: Gillette Children’s, a pediatric healthcare system, opposes the proposed rule because it would burden rare disease research through the marginalization of expert peer review and the restriction of international collaborations. They also argue that the proposed discretionary termination authority would destroy the scientific value of long-term longitudinal studies.